sr141716 has been researched along with Cirrhosis, Liver in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cinar, R; Coffey, NJ; Erdelyi, K; Gao, M; Iyer, MR; Jourdan, T; Katz, A; Kunos, G; Pacher, P | 1 |
| Hassan, R; Mahmoud, MF; Rezq, S | 1 |
| El Achy, SN; Issa, YA; Mady, RF | 1 |
| Baldassarre, M; Caraceni, P; Giannone, FA; Napoli, L; Ricci, CS; Tovoli, A; Tufoni, M | 1 |
| Gao, Y; Guan, D; Jiang, S; Li, S; Liu, M; Tian, Z; Wang, L; Zhang, M | 1 |
| Dai, E; Jiang, H; Jiang, X; Li, X; Liu, H; Ma, J; Wang, Y; Yang, L; Ye, L; Zhang, D; Zhang, J | 1 |
| Atkinson, RD; DeLeve, LD; Kanel, GC; McCuskey, RS; Wang, X | 1 |
| Lotersztajn, S; Mallat, A | 1 |
| Deveaux, V; Grenard, P; Julien, B; Ledent, C; Li, L; Lotersztajn, S; Mallat, A; Serriere-Lanneau, V; Teixeira-Clerc, F; Tran Van Nhieu, J | 1 |
| Nau, JY | 1 |
| Deveaux, V; Hezode, C; Lotersztajn, S; Mallat, A; Teixeira-Clerc, F; Tran van Nhieu, J | 1 |
| Senior, K | 1 |
3 review(s) available for sr141716 and Cirrhosis, Liver
| Article | Year |
|---|---|
The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.
Topics: Cannabinoid Receptor Antagonists; Endocannabinoids; Gene Expression Regulation; Humans; Liver Cirrhosis; Models, Biological; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Signal Transduction | 2013 |
[Research progress of role of cannabinoid receptor in fibrosis].
Topics: Animals; Cannabinoid Receptor Antagonists; Cannabinoids; Fibrosis; Humans; Liver Cirrhosis; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Rimonabant; Scleroderma, Diffuse; Signal Transduction; Skin; Smad Proteins; Transforming Growth Factor beta1 | 2014 |
Endocannabinoids and their role in fatty liver disease.
Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Endocannabinoids; Fatty Liver; Humans; Hypertension, Portal; Inflammation; Insulin Resistance; Liver Cirrhosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant | 2010 |
9 other study(ies) available for sr141716 and Cirrhosis, Liver
| Article | Year |
|---|---|
Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB
Topics: Animals; Brain; CHO Cells; Cricetinae; Cricetulus; Drug Design; Enzyme Inhibitors; Humans; Liver Cirrhosis; Mice; Nitric Oxide Synthase Type II; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2017 |
Rimonabant ameliorates hepatic ischemia/reperfusion injury in rats: Involvement of autophagy via modulating ERK- and PI3K/AKT-mTOR pathways.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Cannabinoid Receptor Antagonists; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hepatitis; Inflammation Mediators; Lipid Peroxidation; Liver; Liver Cirrhosis; Male; Oxidative Stress; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats, Wistar; Receptor, Cannabinoid, CB1; Reperfusion Injury; Rimonabant; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model.
Topics: Actins; Animals; Anthelmintics; Cannabinoid Receptor Antagonists; Drug Therapy, Combination; Granuloma; Immunohistochemistry; Liver Cirrhosis; Male; Mice; Myofibroblasts; Praziquantel; Receptor, Cannabinoid, CB1; Reproducibility of Results; Rimonabant; Schistosomiasis; Treatment Outcome | 2019 |
Rimonabant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells.
Topics: Animals; Apoptosis; Cannabinoid Receptor Antagonists; Caspase 3; Cell Line; Cell Proliferation; Collagen; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Kinase 1; G2 Phase Cell Cycle Checkpoints; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Phosphorylation; Piperidines; Pyrazoles; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Time Factors | 2014 |
Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis.
Topics: Actins; Animals; Apolipoprotein A-I; Body Weight; Cells, Cultured; Diet; Disease Models, Animal; Fatty Liver; Hepatocytes; Inflammation; Liver; Liver Cirrhosis; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Organ Size; Piperidines; Pyrazoles; Rimonabant | 2008 |
CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.
Topics: Animals; Cannabinoid Receptor Modulators; Disease Progression; Female; Humans; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Retrospective Studies; Rimonabant; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2006 |
[Blockage of the CB1 cannabinoid receptor for the prevention of liver cirrhosis ].
Topics: Animals; Liver; Liver Cirrhosis; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2006 |
[Endocannabinoids: therapeutic perspectives in chronic liver diseases].
Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2007 |
Endogenously produced cannabinoids and liver cirrhosis.
Topics: Animals; Arachidonic Acids; Cannabinoids; Endocannabinoids; Humans; Liver; Liver Cirrhosis; Liver Cirrhosis, Experimental; Piperidines; Polyunsaturated Alkamides; Portal Pressure; Pyrazoles; Rats; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Vasodilation | 2001 |